Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Jefferies Downgrades Tourmaline Bio (TRML) to Hold
September 9, 2025 3:04 PM EDTJefferies analyst Roger Song downgraded Tourmaline Bio (NASDAQ: TRML) from Buy to Hold with a price target of $47.50 (from $64.00).
The analyst comments "NVS announced to acquire TRML at $48/ share (~60%/ ~130% premium to D0/ 60D- VWAP), totaling ~$1.4B equity value (~$1.1B+ EV... More
Guggenheim Downgrades Tourmaline Bio (TRML) to Neutral
September 9, 2025 8:19 AM EDTGuggenheim analyst Yatin Suneja downgraded Tourmaline Bio (NASDAQ: TRML) from Buy to Neutral.
The analyst comments "We are updating our PT and downgrading TRML to Neutral to reflect the $48/share (~$1.4Bn in total) acquisition price Novartis has agreed to pay for Tourmaline Bio. This deal is centered around TRML's... More
